Exatecan mesilate

N/A

Report date: 2023/04/25 13:50:57
NME

Base Information

Drug NameExatecan mesilate
Drug Alias Nameexatecanum甲磺酸依沙替康依沙替康Exatecan mesylateDX-8951 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[8] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co LtdYakult Honsha Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteDaiichi Sankyo Co LtdDaiichi Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorSolid tumoursMyelodysplastic Syndromes +[19] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG